MedTrace Logo

Preoperative Ondansetron Lozenge for Prevention of Postoperative Nausea and Vomiting in Caesarean Section

NCT06254131 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-10-22

No results posted yet for this study

Summary

The aim of this study is to estimate the effect of preoperative ondansetron lozenge on prevention of postoperative nausea and vomiting in caesarean section.

Conditions

  • Ondansetron Lozenge
  • Postoperative Nausea and Vomiting
  • Caesarean Section

Interventions

DRUG

Ondansetron lozenge (Ondalenz ©)

Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.

DRUG

Ondansetron IV

Patients will receive 4 mg of ondansetron IV approximately 30 minutes before the end of surgery.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-10
Primary Completion
2024-10-05
Completion
2024-10-05

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06254131 on ClinicalTrials.gov